Harrow Health, Inc. (HROW)
NASDAQ: HROW · IEX Real-Time Price · USD
20.85
-0.20 (-0.95%)
Jul 2, 2024, 4:00 PM EDT - Market closed
Harrow Health Revenue
Harrow Health had revenue of $138.68M in the twelve months ending March 31, 2024, with 49.79% growth year-over-year. Revenue in the quarter ending March 31, 2024 was $34.59M with 32.50% year-over-year growth. In the year 2023, Harrow Health had annual revenue of $130.19M with 46.95% growth.
Revenue (ttm)
$138.68M
Revenue Growth
+49.79%
P/S Ratio
5.32
Revenue / Employee
$440,244
Employees
315
Market Cap
737.71M USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 130.19M | 41.60M | 46.95% |
Dec 31, 2022 | 88.60M | 16.12M | 22.24% |
Dec 31, 2021 | 72.48M | 23.61M | 48.30% |
Dec 31, 2020 | 48.87M | -2.29M | -4.48% |
Dec 31, 2019 | 51.17M | 9.79M | 23.67% |
Dec 31, 2018 | 41.37M | 14.60M | 54.52% |
Dec 31, 2017 | 26.77M | 6.83M | 34.26% |
Dec 31, 2016 | 19.94M | 10.23M | 105.25% |
Dec 31, 2015 | 9.72M | 8.06M | 485.30% |
Dec 31, 2014 | 1.66M | 1.65M | 16,500.00% |
Dec 31, 2013 | 10.00K | -90.00K | -90.00% |
Dec 31, 2012 | 100.00K | - | - |
Dec 31, 2011 | 0 | - | - |
Dec 31, 2010 | 0 | - | - |
Dec 31, 2009 | 0 | - | - |
Dec 31, 2008 | 0 | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Embecta | 1.13B |
Ginkgo Bioworks Holdings | 208.70M |
Cytek Biosciences | 200.79M |
CureVac | 64.13M |
Mesoblast | 7.25M |
Dianthus Therapeutics | 2.26M |
HROW News
- 12 days ago - Harrow Provides TRIESENCE® Relaunch Update - Business Wire
- 26 days ago - Melt Pharmaceuticals Announces First Patient Dosed in Pivotal Phase 3 Program of Its Lead Product Candidate, MELT-300, for Needle- and Opioid-Free Sedation in Patients Undergoing Cataract Surgery - Business Wire
- 27 days ago - Harrow Announces 52-Week Data from VEVYE® ESSENCE-2 Open-Label Extension Study - Business Wire
- 6 weeks ago - Harrow to Present at Two Investor Conferences in May - Business Wire
- 7 weeks ago - Harrow Announces First Quarter 2024 Financial Results - Business Wire
- 7 weeks ago - Harrow Names Greg DiPasquale as Senior Vice President, Head of Commercial - Business Wire
- 2 months ago - Harrow Will Release First Quarter 2024 Financial Results After Market Close on May 13, 2024 - Business Wire
- 3 months ago - Melt Pharmaceuticals Closes $24 Million Series B Preferred Stock Financing - Business Wire